Search hospitals > Michigan > Kalamazoo
Bronson Methodist Hospital
Claim this profileKalamazoo, Michigan 49007
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Leukemia
Conducts research for Tumors
Conducts research for Recurrence
544 reported clinical trials
5 medical researchers
Summary
Bronson Methodist Hospital is a medical facility located in Kalamazoo, Michigan. This center is recognized for care of Cancer, Breast Cancer, Leukemia, Tumors, Recurrence and other specialties. Bronson Methodist Hospital is involved with conducting 544 clinical trials across 676 conditions. There are 5 research doctors associated with this hospital, such as Kathleen J. Yost, Mark Goetting, MD, Gregory Wiggins, MD, and Chris Sloffer, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Kathleen J. YostBronson Methodist Hospital7 years of reported clinical research
Expert in Cancer
Expert in Tumors
223 reported clinical trials
339 drugs studied
Mark Goetting, MDBronson Sleep Health2 years of reported clinical research
Studies Excessive Daytime Sleepiness
Studies Idiopathic Hypersomnia
3 reported clinical trials
4 drugs studied
Gregory Wiggins, MDBronson Methodist Hospital7 years of reported clinical research
Studies Disease
Studies Degenerative Lumbosacral Spinal Conditions
1 reported clinical trial
2 drugs studied
Chris Sloffer, MDBronson Methodist Hospital7 years of reported clinical research
Studies Disease
Studies Degenerative Lumbosacral Spinal Conditions
1 reported clinical trial
2 drugs studied
Clinical Trials running at Bronson Methodist Hospital
Breast Cancer
Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Gastric Cancer
Multiple Myeloma
Pancreatic Cancer
Tumors
Ovarian Cancer
Osteosarcoma
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Bronson Methodist Hospital?
Bronson Methodist Hospital is a medical facility located in Kalamazoo, Michigan. This center is recognized for care of Cancer, Breast Cancer, Leukemia, Tumors, Recurrence and other specialties. Bronson Methodist Hospital is involved with conducting 544 clinical trials across 676 conditions. There are 5 research doctors associated with this hospital, such as Kathleen J. Yost, Mark Goetting, MD, Gregory Wiggins, MD, and Chris Sloffer, MD.
Where is Bronson Methodist Hospital located?
Bronson Methodist Hospital is located at 601 John St, Kalamazoo, MI 49007, in the city center. It serves as a regional medical center and children's hospital for southwest Michigan.
Who should I call to ask about financial aid or insurance network?
**Bronson Methodist Hospital Financial Assistance and Insurance Inquiries:**
- **Financial Assistance:** Contact the Billing Department at (269) 341-6117 or (800) 699-6117, Monday - Friday, 8:30 a.m. - 5:30 p.m.
- **Insurance Inquiries:**
- Bronson Battle Creek Hospital: (269) 245-8124
- Bronson LakeView Hospital: (269) 657-1532
- Bronson Methodist Hospital: (269) 341-6120
- Bronson Behavioral Health Hospital: (269) 443-1521
- **Medicare Enrollment:** Call Social Security at 1-800-772-1213 or visit socialsecurity.gov.
What insurance does Bronson Methodist Hospital accept?
Bronson Methodist Hospital accepts a wide range of insurance plans, such as Meridian Health Plan Medicaid, Meridian Health Plan Medicare, UnitedHealthcare, Aetna, Blue Cross Blue Shield of Michigan, Blue Care, Humana, and Priority Health. It's important to verify your individual coverage with your insurance carrier, as insurance coverage can change.
What awards or recognition has Bronson Methodist Hospital received?
Bronson Methodist Hospital, located in Kalamazoo, Michigan, is a recipient of the 2005 Malcolm Baldrige National Quality Award, the highest presidential honor for quality and organizational performance excellence in the nation. It has also been acknowledged by the Leapfrog Group as one of the safest hospitals in the country and is recognized as a national leader in the development of electronic health records.